American Journal of Hematology最新文献

筛选
英文 中文
Real-World Experience of Mitapivat in Pyruvate Kinase Deficiency 米他伐特治疗丙酮酸激酶缺乏症的实际经验。
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-06 Epub Date: 2026-09-18 DOI: 10.1002/ajh.70504
Giacinto Luca Pedone, Paolo Ricchi, Michela Ribersani, Francesco Arcioni, Teresa Ceglie, Filippo Mazzi, Antonella Sau, Maria Pia Solfrizzi, Caterina Giovanna Valentini, Anna Marcello, Paola Bianchi, Marta Bortolotti, Francesco Passamonti, Wilma Barcellini, Bruno Fattizzo
{"title":"Real-World Experience of Mitapivat in Pyruvate Kinase Deficiency","authors":"Giacinto Luca Pedone, Paolo Ricchi, Michela Ribersani, Francesco Arcioni, Teresa Ceglie, Filippo Mazzi, Antonella Sau, Maria Pia Solfrizzi, Caterina Giovanna Valentini, Anna Marcello, Paola Bianchi, Marta Bortolotti, Francesco Passamonti, Wilma Barcellini, Bruno Fattizzo","doi":"10.1002/ajh.70504","DOIUrl":"10.1002/ajh.70504","url":null,"abstract":"<p>Pyruvate kinase deficiency (PKD) is the most frequent congenital non-spherocytic hemolytic anemia, caused by biallelic PKLR mutations that reduce erythrocyte ATP and drive chronic hemolysis with ineffective erythropoiesis [<span>1</span>]. The phenotype is highly heterogeneous and, until recently, management was confined to supportive measures [<span>2, 3</span>]. Mitapivat, an oral allosteric pyruvate kinase (PK) activator, is the first disease-modifying therapy approved for PKD [<span>4</span>], with efficacy established in the Phase 2 DRIVE-PK [<span>5</span>] and Phase 3 ACTIVATE [<span>6</span>] and ACTIVATE-T [<span>7</span>] trials. Because the Phase 3 trials had restrictive eligibility criteria, requiring at least one missense PKLR allele [<span>6, 7</span>], real-world outcomes across the full genotypic spectrum remain underexplored. We report the first multicenter real-world analysis of mitapivat in adults with PKD.</p><p>We retrospectively analyzed 19 consecutive adults with PKD who received mitapivat in routine practice through patient-named use programs at nine Italian centers. Patients with any previous exposure to mitapivat in clinical trials were excluded. Standard drug titration (5 mg twice daily, escalated to 20 and 50 mg by response and tolerability) was followed. Laboratory parameters were monitored at baseline, at weeks 4, 8, 12, 24 and 48, and at last follow-up. PKD was diagnosed by reduced PK enzyme activity and/or biallelic PKLR variants; genotype was unavailable in four patients, in whom diagnosis rested on enzyme activity and phenotype. Response was defined as a hemoglobin (Hb) increase of at least 1.5 g/dL at two or more consecutive assessments, or a reduction of at least 33% in transfusion burden within 48 weeks in regularly transfused patients; complete response required normal sex-specific Hb and normalization of hemolytic markers. The study followed the Declaration of Helsinki with institutional approval and informed consent. Continuous and categorical variables were compared with Wilcoxon and Fisher exact tests, respectively. Genotype groups were compared with the Kruskal-Wallis test. Medians and interquartile ranges (IQR) are reported for descriptive statistics.</p><p>The cohort comprised 8 men and 11 women, median age 50 (38–65) years (Table 1). Among 16 patients with available genotypes, 11 (69%) carried biallelic missense variants, 3 (19%) missense/non-missense variants, and 2 (12%) biallelic non-missense variants; 8 (50%) were compound heterozygous. At baseline, median Hb was 9.5 (9.0–10.2) g/dL, 8 (42%) were regularly transfused, 12 (63%) splenectomized, and 9 (47%) on iron chelation. Comorbidities were uncommon: one patient with coexistent glucose-6-phosphate dehydrogenase deficiency and one with choledocholithiasis.</p><p>Over a median follow-up of 19 (10–25) months, 14 of 19 patients (74%) responded: 12 (63%) achieved an Hb increase of at least 1.5 g/dL, and 6 of 8 (75%) regularly transfused patients re","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3054-3058"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70504","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninvasive Diagnosis of Splenosis Using Tc-99m Heat-Denatured Red Blood Cell Scintigraphy 使用Tc - 99m热变性红细胞显像无创诊断脾病
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-06 Epub Date: 2026-09-09 DOI: 10.1002/ajh.70501
Natacha Dewarrat, Katharina Auf der Springe, Francesco Grandoni, Rami Hajri, Mathilde Gavillet
{"title":"Noninvasive Diagnosis of Splenosis Using Tc-99m Heat-Denatured Red Blood Cell Scintigraphy","authors":"Natacha Dewarrat, Katharina Auf der Springe, Francesco Grandoni, Rami Hajri, Mathilde Gavillet","doi":"10.1002/ajh.70501","DOIUrl":"10.1002/ajh.70501","url":null,"abstract":"<p>A 23-year-old patient was referred to our out-patient clinic for the investigation of abdominal masses discovered during a gynecological examination.</p><p>The patient's medical history was notable for hereditary spherocytosis treated by splenectomy 5 years earlier, resulting in complete resolution of anemia and, later, loss to hematological follow-up. The blood count was consistent with the expected post-splenectomy profile: hemoglobin 142 g/L (117–157 g/L) with reticulocytosis (122.8 × 10<sup>9</sup>/L; 20–120 × 10<sup>9</sup>/L), thrombocytosis 444 × 10<sup>9</sup>/L (150–350 × 10<sup>9</sup>/L). Haptoglobin was undetectable (< 0.1 g/L; 0.3–2 g/L) and the other hemolysis parameters (LDH, total bilirubin) were within the normal range. The blood smear examination demonstrated spherocytes, Howell-Jolly bodies, polychromasia, and occasional erythroblasts. Neither peripheral blood smear nor flow cytometry provided evidence of circulating lymphoproliferative disease. A pelvic MRI showed well-defined and contrast-enhancing masses without signs of tissue invasion (Figure 1A,B,E), the largest measuring 44 mm. Following additional contrast-enhanced CT evaluation (Figure 1D), the differential diagnosis included splenosis and lymphoma, and a biopsy was recommended.</p><p>At this stage of the investigations, ectopic splenic tissue was deemed unlikely given to the presence of numerous Howell body bodies as well as persistent thrombocytosis. Conversely, lymphoma could neither be confirmed nor excluded. Although tissue biopsy represents the diagnostic gold standard to elucidate the nature of the masses, a percutaneous transabdominal approach carried a substantial risk of bleeding due to their anatomical location.</p><p>The patient subsequently underwent selective spleen scintigraphy using technetium-99 m-labeled, heat-damaged red blood cells with Single-Photon Emission Computed Tomography/Computed Tomography (SPECT/CT). This well-established technique is available in specialized nuclear medicine centers worldwide equipped with radio-pharmaceutical facilities capable of processing blood samples. Following intravenous administration of stannous pyrophosphate to facilitate intracellular trapping of technetium within red blood cells, a small peripheral blood sample (typically around 5 mL) is collected. The red blood cells are then isolated by centrifugation, heat damaged (e.g., heated for 20 min in a water bath at 49.5°C/121°F, stirring every 5 min) and incubated with technetium-99 m pertechnetate. Subsequently, the resulting radiolabeled red blood cells are reinjected intravenously [<span>1</span>]. Owing to the spleen's physiological filtering function, the damaged labeled erythrocytes selectively accumulate within splenic tissue. In our patient, SPECT/CT demonstrated intense tracer uptake in multiple peritoneal nodules, confirming the diagnosis of splenosis (Figure 1C,F).</p><p>Notably, ectopic splenic tissue, due to its limited mass, disorganized archit","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3034-3035"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70501","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148915497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clonally Related Chronic Lymphocytic Leukemia and Malignant Histiocytic Neoplasm (Histiocytic Sarcoma With Overlapping Langerhans Cell Phenotype): Divergent Evolution From a Shared Cell-Of-Origin 克隆相关慢性淋巴细胞白血病和恶性组织细胞肿瘤(具有重叠朗格汉斯细胞表型的组织细胞肉瘤):来自共享细胞起源的不同进化
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-06 Epub Date: 2026-09-05 DOI: 10.1002/ajh.70494
Adelaide J. Kwon, Lindsay K. Hill, Reiko Tachibana, Estelle Oertling, Lin He, Jeffrey Gagan, Prasad Koduru, Franklin Fuda, Jing Xu, Miguel Cantu, Stephen Chung, Benjamin Kroger, Praveen Ramakrishnan Geethakumari, Weina Chen
{"title":"Clonally Related Chronic Lymphocytic Leukemia and Malignant Histiocytic Neoplasm (Histiocytic Sarcoma With Overlapping Langerhans Cell Phenotype): Divergent Evolution From a Shared Cell-Of-Origin","authors":"Adelaide J. Kwon, Lindsay K. Hill, Reiko Tachibana, Estelle Oertling, Lin He, Jeffrey Gagan, Prasad Koduru, Franklin Fuda, Jing Xu, Miguel Cantu, Stephen Chung, Benjamin Kroger, Praveen Ramakrishnan Geethakumari, Weina Chen","doi":"10.1002/ajh.70494","DOIUrl":"10.1002/ajh.70494","url":null,"abstract":"<p>Malignant histiocytic neoplasms (MHNs) are rare, aggressive malignancies that suffer from diagnostic complexity and poor prognosis [<span>1, 2</span>]. MHNs arise from cells of the mononuclear phagocyte system and include histiocytic sarcoma (HS), Langerhans cell sarcoma (LCS), interdigitating dendritic cell sarcoma, and high-grade indeterminate dendritic cell tumors. They are typically distinguished by their immunophenotypic profiles, although rare cases with overlapping features have been described [<span>3, 4</span>]. MHNs can arise <i>de novo</i> (primary, pMHN) or in association with various hematological malignancies (secondary, sMHN) and can occur in nodal and extranodal sites. Some cases of sMHN demonstrate clonal relatedness to co-occurring or antecedent hematologic neoplasms, including follicular lymphoma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, and acute lymphoblastic leukemia [<span>3, 5-7</span>], suggesting a common ancestral cell-of-origin or de- or trans-differentiation of the prior malignancy. Although activating MAPK pathway alterations have been implicated in MHN pathogenesis [<span>5, 7-9</span>], molecular events determining lineage fates in CLL-associated sMHN are not fully elucidated.</p><p>Herein, we describe the first case to our knowledge of clonally related CLL and sMHN (histiocytic sarcoma with overlapping Langerhans cell phenotype) (MHN HS-LCP) determined by whole exome and genome sequencing (WES, WGS) and PCR analysis of immunoglobulin (IG) gene rearrangement of prospectively sorted CLL and MHN (HS-LCP) cell populations. We postulate that the patient's CLL and sMHN (HS-LCP) arose from a common cell-of-origin through divergent evolution and discuss the molecular pathogenesis driving lineage bifurcation.</p><p>A 66-year-old female with an extensive family history of cancer, including ovarian, esophageal, lung, and colon cancers, as well as lymphoma, and an 11-year history of CLL treated with rituximab with and without bendamustine, followed by 4 years of ibrutinib monotherapy presented with dyspnea, fatigue, and lymphadenopathy. Computed tomography imaging revealed extensive multi-station lymphadenopathy and splenomegaly. Peripheral blood (PB), bone marrow (BM), and lymph node (LN) samples were submitted for morphology, immunohistochemical/flow cytometric immunophenotyping, cytogenetics/fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). LN and BM biopsies demonstrated co-existing CLL and MHN (HS-LCP). The patient was started on ifosfamide, carboplatin, and etoposide, but succumbed to progressive disease 2 months after symptom onset.</p><p>PB analysis showed anemia, thrombocytopenia, occasional CLL cells (17%), and rare MHN (HS-LCP) cells (< 0.5%), while LN and BM biopsies demonstrated CLL and MHN (HS-LCP) infiltration (Figure 1A,B). CLL cells were small with a typical immunophenotype of CD5(+)/CD19(+)/PAX5(+)/cyclin D1(−) (Figure 1C). MHN (HS-LCP) cells were large","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3036-3042"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70494","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients Venetoclax加低甲基化剂治疗新诊断急性髓性白血病7天、14天、21天、28天周期:540例患者的ELN和Mayo遗传风险分层分析
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-06 Epub Date: 2026-09-17 DOI: 10.1002/ajh.70500
Sudhesh Kumar, Momna Warraich, Mahnoor Fatima, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, James Foran, Jeanne Palmer, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat
{"title":"Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients","authors":"Sudhesh Kumar,&nbsp;Momna Warraich,&nbsp;Mahnoor Fatima,&nbsp;Kristen McCullough,&nbsp;Aref Al-Kali,&nbsp;Hassan B. Alkhateeb,&nbsp;Kebede H. Begna,&nbsp;Abhishek A. Mangaonkar,&nbsp;Antoine N. Saliba,&nbsp;Mark R. Litzow,&nbsp;William Hogan,&nbsp;Mithun Shah,&nbsp;Mrinal M. Patnaik,&nbsp;Animesh Pardanani,&nbsp;Talha Badar,&nbsp;James Foran,&nbsp;Jeanne Palmer,&nbsp;Cecilia Arana Yi,&nbsp;Ayalew Tefferi,&nbsp;Naseema Gangat","doi":"10.1002/ajh.70500","DOIUrl":"10.1002/ajh.70500","url":null,"abstract":"<div>\u0000 \u0000 <p>Patients with newly-diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax (Ven) plus hypomethylating agent (HMA) therapy, and the optimal Ven duration across genetic risk groups remains undefined. Among 540 ND-AML patients receiving Ven-HMA at Mayo Clinic, outcomes were compared across Ven 7- (<i>n</i> = 33), 14- (<i>n</i> = 117), 21- (<i>n</i> = 96), and 28-day (<i>n</i> = 294) schedules during Cycle 1 and stratified by ELN 2024 and Mayo genetic risk groups. At a median follow-up of 37.7 months, allogeneic stem cell transplant (ASCT) rates were similar across Ven duration groups (15%, 18%, 18%, and 20% for 7-, 14-, 21-, and 28-day; <i>p</i> = 0.86). Median transplant-censored survival was comparable across Ven durations (13.3, 11.9, 16.8, and 13.2 months for 7, 14, 21, 28 days, respectively; <i>p</i> = 0.65), with outcomes driven by ELN risk (6.3, 11.5, 18.3 months for high, intermediate, low; <i>p</i> &lt; 0.01) and Mayo genetic risk (6.9, 17.8 months, not reached; <i>p</i> &lt; 0.01). Survival was comparable across Ven durations within ELN intermediate/low-risk and all Mayo risk groups. Among ELN high-risk patients, 14-day Ven was associated with inferior transplant-censored survival compared to 21- and 28-day schedules (<i>p</i> &lt; 0.01). Notably, 30- and 60-day mortality were higher with shorter Ven schedules (7-day: 9%/18%; 14-day: 7%/15%) versus 28-day (2%/6%), which likely reflects treatment selection bias. In ND-AML, no significant difference in transplant-censored survival was observed across the 7-, 14-, 21-, and 28-day Ven schedules; prognosis was determined primarily by Mayo and ELN 2024 genetic risk rather than by Ven duration. Prospective trials are needed to establish risk-adapted Ven dosing strategies.</p>\u0000 </div>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"2990-3000"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Effector Cell Therapies for Immune Thrombocytopenia Concurrent With Hematologic Malignancy 免疫效应细胞治疗免疫性血小板减少并发血液恶性肿瘤
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-06 Epub Date: 2026-09-23 DOI: 10.1002/ajh.70505
Saarang R. Deshpande, Debbie Jiang, Rebecca K. Leaf, Andrew Song, P. Connor Johnson, Caron Jacobson, Jeremy Abramson, Hanny Al-Samkari
{"title":"Immune Effector Cell Therapies for Immune Thrombocytopenia Concurrent With Hematologic Malignancy","authors":"Saarang R. Deshpande,&nbsp;Debbie Jiang,&nbsp;Rebecca K. Leaf,&nbsp;Andrew Song,&nbsp;P. Connor Johnson,&nbsp;Caron Jacobson,&nbsp;Jeremy Abramson,&nbsp;Hanny Al-Samkari","doi":"10.1002/ajh.70505","DOIUrl":"10.1002/ajh.70505","url":null,"abstract":"&lt;p&gt;Primary and secondary immune thrombocytopenia (ITP) are differentiated by the presence or absence of an underlying driver (lymphoid malignancy, infection, or autoimmune disease), but share a pathophysiology involving platelet glycoprotein-specific antibody-mediated and antibody-independent platelet destruction and inadequate thrombopoiesis [&lt;span&gt;1&lt;/span&gt;]. Immune effector cell (IEC) therapies, including chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engager (TCE) therapies, are increasingly used in lymphomas and plasma cell disorders [&lt;span&gt;2-5&lt;/span&gt;]. They have also demonstrated promising efficacy across autoimmune diseases, including ITP [&lt;span&gt;6-8&lt;/span&gt;], by inducing deeper immunologic disruption of the autoreactive B cell and long-lived plasma cells that may preserve autoimmune memory, contribute to ITP relapse, and remain incompletely depleted by traditional ITP therapy such as rituximab [&lt;span&gt;9-16&lt;/span&gt;]. Evidence for IEC therapy in ITP secondary to malignancy, however, remains sparse [&lt;span&gt;13-15, 17&lt;/span&gt;]. Therefore, we conducted a multicenter observational study to characterize the efficacy of IEC therapies for ITP concurrent with malignancy.&lt;/p&gt;&lt;p&gt;The study was approved by the Institutional Review Board of Mass General Brigham (MGB; approval # 2026P001744). Adults treated with investigational or approved IEC therapies between 2017 and 2026 were identified through the MGB Research Patient Data Registry if they had an ICD-9/10 code for ITP to clinical documentation of ITP. Records were reviewed to identify eligible patients with a biopsy-proven malignancy and concurrent secondary ITP (consistent with international guidelines [&lt;span&gt;18&lt;/span&gt;]) that was not in complete response (CR) at the time of IEC therapy. To ensure accurate adjudication of ITP, we utilized a targeted database query and excluded patients with pancytopenia, active infection, or autoimmune disease, followed by manual chart review by classical hematologists.&lt;/p&gt;&lt;p&gt;The primary outcome was platelet response by the International Working Group (IWG) criteria: platelet count ≥ 30 × 10&lt;sup&gt;9&lt;/sup&gt;/L (on ≥ 2 measurements at least 7 days apart), doubling of the baseline count, and no clinically significant bleeding. The key secondary endpoint was CR: improvement to ≥ 100 × 10&lt;sup&gt;9&lt;/sup&gt;/L. [&lt;span&gt;18&lt;/span&gt;] Secondary endpoints included time to platelet response, ITP response duration, time to malignancy progression, and safety. Response duration was estimated by the Aalen-Johansen method with a death as a competing risk.&lt;/p&gt;&lt;p&gt;Of 539 patients reviewed, 22 (4.1%) met inclusion criteria. Indications for exclusion included more plausible causes of thrombocytopenia other than ITP (&lt;i&gt;n&lt;/i&gt; = 476); thrombocytopenia after, rather than before, IEC therapy (&lt;i&gt;n&lt;/i&gt; = 23); and ITP in CR prior to IEC therapy (&lt;i&gt;n&lt;/i&gt; = 18). At ITP diagnosis, 10 (45%) patients had not yet received anti-neoplastic therapy, 9 (41%) had previously been treated but were now on","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 12","pages":"3067-3071"},"PeriodicalIF":9.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70505","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Follicular Lymphoma: 2027 Annual Update. 滤泡性淋巴瘤:2027年度更新。
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-04 DOI: 10.1002/ajh.70551
Bret Wankel, Carla Casulo
{"title":"Follicular Lymphoma: 2027 Annual Update.","authors":"Bret Wankel, Carla Casulo","doi":"10.1002/ajh.70551","DOIUrl":"https://doi.org/10.1002/ajh.70551","url":null,"abstract":"<p><strong>Background: </strong>Follicular lymphoma (FL) is the most common indolent lymphoma and has widely variable disease trajectories. While patients with a durable response to initial therapy have expected survival comparable to the general population, patients with early or recurrent relapses, or with transformation to large cell lymphoma, are at serious risk of lymphoma-associated death.</p><p><strong>Summary: </strong>This review discusses the biological and clinical characteristics of FL as well as diagnostic assessment, prognostic tools, and treatment options.</p><p><strong>Conclusion: </strong>Targeted therapies, bispecific antibodies, and CAR-T cell therapies offer exciting new options for historically difficult-to-treat disease. Sequencing of novel therapies and their use earlier in treatment are areas of ongoing investigation. Recent data suggest FL may be cured in a portion of patients treated with chemoimmunotherapy. Minimal residual disease testing is a highly predictive test for progression and may have a role in FL management in the future.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL. 评估吡托布替尼单药治疗MCL患者安全性和有效性的BRUIN 1/2期研究的最终分析。
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-04 DOI: 10.1002/ajh.70533
Michael L Wang, Jonathon B Cohen, Nirav N Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y Cheah, Chaitra S Ujjani, Youngil Koh, Won Seog Kim, Sunita D Nasta, Ian Flinn, Benoit Tessoulin, Shuo Ma, Alvaro J Alencar, David J Lewis, Jennifer A Woyach, Kami J Maddocks, Krish Patel, Yucai Wang, Joanna M Rhodes, Constantine S Tam, John F Seymour, Hirokazu Nagai, Julie M Vose, Bita Fakhri, Marc S Hoffmann, Francisco Hernandez-Ilizaliturri, Andrew D Zelenetz, Anita Kumar, Talha Munir, Donald E Tsai, Paolo Abada, Minna Balbas, Jian Li, Denise Wang, Lindsey E Roeker, Toby A Eyre
{"title":"Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL.","authors":"Michael L Wang, Jonathon B Cohen, Nirav N Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y Cheah, Chaitra S Ujjani, Youngil Koh, Won Seog Kim, Sunita D Nasta, Ian Flinn, Benoit Tessoulin, Shuo Ma, Alvaro J Alencar, David J Lewis, Jennifer A Woyach, Kami J Maddocks, Krish Patel, Yucai Wang, Joanna M Rhodes, Constantine S Tam, John F Seymour, Hirokazu Nagai, Julie M Vose, Bita Fakhri, Marc S Hoffmann, Francisco Hernandez-Ilizaliturri, Andrew D Zelenetz, Anita Kumar, Talha Munir, Donald E Tsai, Paolo Abada, Minna Balbas, Jian Li, Denise Wang, Lindsey E Roeker, Toby A Eyre","doi":"10.1002/ajh.70533","DOIUrl":"https://doi.org/10.1002/ajh.70533","url":null,"abstract":"<p><p>Pirtobrutinib, a highly selective, non-covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL). Here, we report final results from the global Phase 1/2 BRUIN trial evaluating pirtobrutinib in patients with R/R MCL, with and without prior cBTKi exposure. Endpoints included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. BRUIN enrolled 166 patients with R/R MCL (data cutoff: 27Jan2025). In the cBTKi-exposed cohort (n = 152), median study follow-up time was 16.1 months (range, 0.5-69.6). The ORR was 49.3% (95% CI, 41.1-57.6). Median DOR was 21.6 months (95% CI, 9.2-27.2). Median PFS was 5.6 months (95% CI, 5.3-9.2; 36-month rate, 19.9%). Median OS was 23.9 months (95% CI, 17.3-51.5; 36-month rate, 43.2%). In the cBTKi-naïve cohort (n = 14), median study follow-up time was 44.5 months (range, 1.6-67.1). The ORR was 85.7% (95% CI, 57.2-98.2). Median DOR was 42.7 months (95% CI, 25.8-not estimable [NE]). Median PFS was 44.6 months (95% CI, 16.7-NE; 36-month rate, 58.7%). Median OS was NE (36-month rate, 76.2%). The most frequent any-grade treatment-emergent adverse events (TEAEs) were infections (44.0%), fatigue (31.9%), and diarrhea (22.9%); the most frequent grade ≥ 3 TEAEs were infections (21.1%) and neutropenia (15.1%). Grade ≥ 3 hemorrhage (3.0%) and any-grade atrial fibrillation/flutter (3.6%) were infrequent. With extended follow-up, pirtobrutinib continued to demonstrate efficacy and favorable safety in cBTKi-exposed and -naïve R/R MCL. Trial Registration: ClinicalTrials.gov identifier: NCT03740529.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Reply to Liu. 给刘的答复
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-02 DOI: 10.1002/ajh.70536
Yifan Han, Xiaoyuan Xu
{"title":"A Reply to Liu.","authors":"Yifan Han, Xiaoyuan Xu","doi":"10.1002/ajh.70536","DOIUrl":"https://doi.org/10.1002/ajh.70536","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Sequencing Yields High Rate of Pathogenic Variants in Both Single and Multilineage Pediatric Immune Cytopenias. 靶向测序在单系和多系儿童免疫细胞减少症中产生高致病性变异率。
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-02 DOI: 10.1002/ajh.70539
Emily M Harris, Thomas Pincez, Kirsty Hillier, Yi-Lee Ting, Irem Eldem, Paul M Gallo, Jennifer MacWhirter-DiRaimo, Hannah Helber, Candelaria O'Farrell, Estelle Lecluze, Laura George, Taylor Olmsted Kim, Rachael F Grace, Michael E Scheurer, Rebecca Hale, Kristin A Shimano, Diane Nugent, Ellis J Neufeld, Craig D Platt, Michele P Lambert, Amanda B Grimes, Shipra Kaicker
{"title":"Targeted Sequencing Yields High Rate of Pathogenic Variants in Both Single and Multilineage Pediatric Immune Cytopenias.","authors":"Emily M Harris, Thomas Pincez, Kirsty Hillier, Yi-Lee Ting, Irem Eldem, Paul M Gallo, Jennifer MacWhirter-DiRaimo, Hannah Helber, Candelaria O'Farrell, Estelle Lecluze, Laura George, Taylor Olmsted Kim, Rachael F Grace, Michael E Scheurer, Rebecca Hale, Kristin A Shimano, Diane Nugent, Ellis J Neufeld, Craig D Platt, Michele P Lambert, Amanda B Grimes, Shipra Kaicker","doi":"10.1002/ajh.70539","DOIUrl":"https://doi.org/10.1002/ajh.70539","url":null,"abstract":"<p><p>Genetically defined IEI was identified in 7.7% of children with immune cytopenias who underwent genetic testing. The high rate of genetic diagnoses in patients with both single- and multi-lineage immune cytopenias who were tested supports the clinical utility of genetic testing in these patients.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robustness of Hemophagocytic Lymphohistiocytosis Risk Estimates in CAR T-Cell Therapy. CAR - t细胞治疗中噬血细胞淋巴组织细胞增多症风险评估的稳健性。
IF 9.4 1区 医学
American Journal of Hematology Pub Date : 2026-11-01 Epub Date: 2026-09-03 DOI: 10.1002/ajh.70492
Changhui Zhang, Hongyan Wu, Weilong Zhang
{"title":"Robustness of Hemophagocytic Lymphohistiocytosis Risk Estimates in CAR T-Cell Therapy.","authors":"Changhui Zhang, Hongyan Wu, Weilong Zhang","doi":"10.1002/ajh.70492","DOIUrl":"10.1002/ajh.70492","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":"2948-2951"},"PeriodicalIF":9.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书